Multiple Combined Drugs To Attack Blood Vessel Formation In Patients With Kidney Cancer

Armen Hareyan's picture
Advertisement

Kidney Cancer

In the first clinical trial of its kind, researchers at the University of Pennsylvania School of Medicine and the Abramson Cancer Center will lead a nationwide test of anti-cancer drug combinations that target blood vessel growth in patients with advanced kidney cancer. The trial is being conducted with colleagues in the Eastern Cooperative Oncology Group, a network of researchers, physicians, and health care professionals at public and private institutions.

Advertisement

In addition to these patients, the results from the trial will inform care in many other types of cancer, including breast, lung, and colon cancer. Penn scientists will also use an experimental imaging technique to measure the effectiveness of the treatments.

The BeST trial stands for bevacizumab(Avastin), sorafenib(Nexavar), and temsirolimus(Torisel), Researchers have previously shown these drugs to slow the progression of metastatic cancer when used alone by starving the cells of the oxygenated blood required for growth.

Advertisement